BMS-986012 in Relapsed/Refractory SCLC

NCT02247349 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

BIOLOGICAL: BMS-986012 (anti-fucosyl-GM1)
BIOLOGICAL: Nivolumab

Sponsor

Bristol-Myers Squibb